{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:50:01Z","timestamp":1791996601911,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"DOI":"10.1186\/s12941-026-00873-4","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:33:12Z","timestamp":1783485192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of cefazolin versus anti-staphylococcal \u03b2-lactam for treating methicillin-susceptible Staphylococcus aureus pneumonia in critically ill patients admitted to intensive care units: a multicenter cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Sufyan M.","family":"Alomair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatun M.","family":"Labban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Damfu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda J.","family":"Aljedaani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad A.","family":"Alshamrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf R.","family":"Altalhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana F.","family":"Albadrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"Alkharfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deem A.","family":"Alkaoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada F.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enas","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad S.","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha A.","family":"Alanizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Almugbil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujain M.","family":"Almatrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa A.","family":"Almehmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram A.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marah","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munirah F.","family":"Alhmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel M.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohoud","family":"Aljuhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"873_CR1","doi-asserted-by":"crossref","unstructured":"Conway Morris AR. Management of pneumonia in intensive care. 2018.","DOI":"10.21037\/jeccm.2018.11.06"},{"key":"873_CR2","doi-asserted-by":"publisher","unstructured":"Li G et al. Jul. Risk factors for mortality in patients admitted to intensive care units with pneumonia. Respir Res. 2016;17(1):80. https:\/\/doi.org\/10.1186\/s12931-016-0397-5.","DOI":"10.1186\/s12931-016-0397-5"},{"issue":"5","key":"873_CR3","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1086\/313440","volume":"29","author":"C Gonz\u00e1lez","year":"1999","unstructured":"Gonz\u00e1lez C, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999;29(5):1171\u20137.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"873_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"J-L Vincent","year":"2020","unstructured":"Vincent J-L, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478\u201387.","journal-title":"JAMA"},{"issue":"4","key":"873_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ajic.2016.11.014","volume":"45","author":"DM Jacobs","year":"2017","unstructured":"Jacobs DM. Prevalence of and outcomes from Staphylococcus aureus pneumonia among hospitalized patients in the United States, 2009\u20132012. Am J Infect Control. 2017;45(4):404\u20139.","journal-title":"Am J Infect Control"},{"issue":"1","key":"873_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/cid\/ciy399","volume":"68","author":"EY Klein","year":"2019","unstructured":"Klein EY, et al. National costs associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010\u20132014. Clin Infect Dis. 2019;68(1):22\u20138.","journal-title":"Clin Infect Dis"},{"key":"873_CR7","doi-asserted-by":"crossref","unstructured":"Gatti M et al. Targeted therapy of severe infections caused by Staphylococcus aureus in critically ill adult patients: a multidisciplinary proposal of therapeutic algorithms based on real-world evidence. Microorganisms. 2023;11.2:394.","DOI":"10.3390\/microorganisms11020394"},{"issue":"2","key":"873_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","volume":"275","author":"MJ Fine","year":"1996","unstructured":"Fine MJ, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA vol. 1996;275(2):134\u201341.","journal-title":"JAMA vol"},{"issue":"9","key":"873_CR9","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1128\/AAC.04677-14","volume":"59","author":"SN Rao","year":"2015","unstructured":"Rao SN, et al. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015;59(9):5232\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"873_CR10","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1128\/AAC.00485-11","volume":"55","author":"S Lee","year":"2011","unstructured":"Lee S, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother. 2011;55(11):5122\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"873_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/cix287","volume":"65","author":"JS McDanel","year":"2017","unstructured":"McDanel JS, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis. 2017;65(1):100\u20136.","journal-title":"Clin Infect Dis"},{"key":"873_CR12","unstructured":"Saudi Critical Care Pharmacy Research (SCAPE) Platform. https:\/\/www.scape-platform.com. Accessed 20 December 2024."},{"key":"873_CR13","doi-asserted-by":"publisher","unstructured":"Lee S, et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea. Clin Microbiol Infect. 2018;24(2):152\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2017.07.001.","DOI":"10.1016\/j.cmi.2017.07.001"},{"issue":"9","key":"873_CR14","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1128\/AAC.02800-14","volume":"58","author":"J Li","year":"2014","unstructured":"Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(9):5117\u201324. https:\/\/doi.org\/10.1128\/AAC.02800-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"873_CR15","doi-asserted-by":"publisher","unstructured":"Yehya N, Harhay MO, Curley MAQ, Schoenfeld DA, Reeder RW. Reappraisal of ventilator-free days in critical care research. Am J Respir Crit Care Med. 2019;200(7):828\u2013836. https:\/\/doi.org\/10.1164\/rccm.201810-2050CP.","DOI":"10.1164\/rccm.201810-2050CP"},{"key":"873_CR16","doi-asserted-by":"publisher","unstructured":"Lee S, Choe PG, Song K, Park S, Kim HB, Kim NJ, Kim E, Park WB, Oh M. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus Bacteremia? Antimicrob Agents Chemother. 2016;55. https:\/\/doi.org\/10.1128\/aac.00485-11.","DOI":"10.1128\/aac.00485-11"},{"key":"873_CR17","doi-asserted-by":"publisher","unstructured":"Monique R, Bidell N, Patel J, O\u2019Donnell N. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018;73:2643\u201351. https:\/\/doi.org\/10.1093\/jac\/dky259.","DOI":"10.1093\/jac\/dky259"},{"issue":"1","key":"873_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.ccm.0000907368.77081.fe","volume":"51","author":"A Jung","year":"2023","unstructured":"Jung A, Jenkins K, Miller C, Smith J, Swartwood C. 410: CEFAZOLIN DOSING IN CRITICALLY ILL PATIENTS FOR THE TREATMENT OF PNEUMONIA. Crit Care Med. 2023;51(1):191.","journal-title":"Crit Care Med"},{"issue":"7","key":"873_CR19","doi-asserted-by":"publisher","first-page":"ofz270","DOI":"10.1093\/ofid\/ofz270","volume":"6","author":"M Beganovic","year":"2019","unstructured":"Beganovic M, Cusumano JA, Lopes V, LaPlante KL, Caffrey AR. Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin\/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis. 2019;6(7):ofz270. https:\/\/doi.org\/10.1093\/ofid\/ofz270.","journal-title":"Open Forum Infect Dis"},{"key":"873_CR20","doi-asserted-by":"publisher","unstructured":"McDanel JS, Roghmann MC, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, Jones M, Albertson JP, Nair R, O\u2019Shea AMJ, Schweizer ML. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis. 2017;65(1):100\u2013106. https:\/\/doi.org\/10.1093\/cid\/cix287.","DOI":"10.1093\/cid\/cix287"},{"key":"873_CR21","doi-asserted-by":"crossref","unstructured":"Corsini Campioli C, Go JR, Abu Saleh O, Challener D, Yetmar Z, Osmon DR. Antistaphylococcal penicillin vs cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus spinal epidural abscesses. Open Forum Infect Dis. 2021;8:ofab071.","DOI":"10.1093\/ofid\/ofab071"},{"key":"873_CR22","doi-asserted-by":"crossref","unstructured":"Lef\u00e8vre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, AEPEI study group (Association pour l\u2019Etude et la Pr\u00e9vention de l\u2019Endocardite Infectieuse). Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. Eur J Clin Microbiol Infect Dis. 2021;40(12):2605\u20132616","DOI":"10.1007\/s10096-021-04313-3"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-026-00873-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-026-00873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-026-00873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:26:00Z","timestamp":1791995160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-026-00873-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1186\/s12941-026-00873-4","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia (Ref. No. 0575\/24; approved April 2024). Patient confidentiality was strictly maintained by using anonymized and unique study identifiers, and access to data was also restricted to the study investigators. The requirement for informed consent was waived due to the retrospective nature of the study, in accordance with institutional and national research guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"42"}}